CSL.AX Berita Valas
CSL Behring Says HEMGENIX Receives Positive Canada Reimbursement Decision
CSL Behring Canada Inc., a business unit of Australian biotechnology company CSL Ltd. (CSL.AX, CMXHF.PK), announced Tuesday that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) recommended public drug plan reimbursement for HEMGENIX (etranacogene dezaparvovec) for the treatment of eligible adults with hemophilia B (congenital factor IX deficiency) who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
RTTNews
|
795 days ago
CSL Vifor Says FDA Grants Partner American Regent Approval For Injectafer To Treat Iron Deficiency
Swiss pharma firm CSL Vifor, a subsidiary of Australia's CSL Ltd. (CSL.AX, CSLLY.PK), announced Monday that the U.S. Food and Drug Administration (FDA) has granted its partner American Regent, Inc., a Daiichi Sankyo Group company, approval for Injectafer for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity.
RTTNews
|
1202 days ago
